Recent news and posts
No new technologies will be added to MedTech Funding Mandate in 2023/24
In November 2022, NHS Accelerated Access Collaborative decided not to add new technologies to MedTech Funding Mandate (MTFM) in 2023/24. Instead, Integrated Care Systems (ICSs) are asked to prioritize the appropriate adoption of eleven currently supported technologies where this has not yet occurred. This decision was made to ensure that the MTFM does not overburden the sector while it continues to recover from the impacts of COVID-19 and embeds ICSs and the new commissioning relationships which underpin system working. The Innovation, Research, and Life Sciences group, along with NICE, NHS Supply Chain, and the Academic Health Science Network (AHSN), will continue to support adopting current MTFM technologies.
The MTFM launched on April 01, 2021, to support NICE-approved and cost-saving devices, diagnostics, and digital products. It is mandatory for commissioners and providers to implement technologies included in MTFM. The scheme is reviewed annually.
Technologies must meet the following criteria to be supported:
- Are effective: demonstrated through positive NICE Medical Technology Guidance (MTG) or Diagnostic Guidance (DG), published by June 30;
- Are cost-saving within three years of implementation: as demonstrated by NICE modeling and published in a NICE resource impact template;
- Are affordable to the NHS: the NICE budget impact analysis total costs should not exceed £20 million in any of the first three years.
See more information here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).